A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group, Single-centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD3199 (a B2-agonist) Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men

Trial Profile

A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group, Single-centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD3199 (a B2-agonist) Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs AZD 3199 (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 May 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 01 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Nov 2008 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top